Oncotelic Therapeutics, Inc. financial data

Symbol
OTLC on OTC
Industry
Pharmaceutical Preparations
Location
29397 Agoura Rd., #107, Aguora Hills, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
MATEON THERAPEUTICS INC (to 3/26/2021), OXIGENE INC (to 6/3/2016)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.6 % -2.44%
Return On Equity -10.7 % +85.3%
Return On Assets -4.13 % +89%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 406M shares +2.04%
Common Stock, Shares, Outstanding 407M shares +2.46%
Entity Public Float 5.36M USD -84.6%
Common Stock, Value, Issued 4.07M USD +2.46%
Weighted Average Number of Shares Outstanding, Basic 402M shares +1.83%
Weighted Average Number of Shares Outstanding, Diluted 399M shares +1.79%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 70K USD
Research and Development Expense 21.2K USD
General and Administrative Expense 400K USD -71%
Operating Income (Loss) -326K USD +97.2%
Nonoperating Income (Expense) -1.18M USD +39.7%
Net Income (Loss) Attributable to Parent -1.24M USD +90.7%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 72.2K USD
Accounts Receivable, after Allowance for Credit Loss, Current 19K USD 0%
Assets, Current 192K USD -31.8%
Goodwill 5.99M USD 0%
Assets 29.9M USD -0.26%
Accounts Payable, Current 343K USD -82.4%
Accrued Liabilities, Current 775K USD -33.5%
Liabilities, Current 16.2M USD -10.4%
Liabilities 18.4M USD
Retained Earnings (Accumulated Deficit) -34.1M USD -3.77%
Stockholders' Equity Attributable to Parent 12.2M USD -1.28%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 11.5M USD -3.54%
Liabilities and Equity 29.9M USD -0.26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -231K USD +7.81%
Net Cash Provided by (Used in) Financing Activities 250K USD +25%
Common Stock, Shares Authorized 750M shares 0%
Common Stock, Shares, Issued 407M shares +2.46%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 18.6K USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 94.8K USD -5.05%
Deferred Tax Assets, Valuation Allowance 13.4M USD -77.3%
Deferred Tax Assets, Gross 13.4M USD -77.3%
Deferred Tax Assets, Operating Loss Carryforwards 10.5M USD -80.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Additional Paid in Capital 42.2M USD +2.39%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 0 USD -100%
Share-based Payment Arrangement, Expense 0 USD
Interest Expense 885K USD -71.1%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%